Background/Objectives: Non-receptive endometrium is associated with recurrent implantation failure, which leads to a decrease in the frequency of pregnancy during IVF; therefore, new treatment methods such as the use of Platelet-Rich Plasma (PRP) are gaining popularity in the treatment of infertility in women with repeated unsuccessful IVF attempts. Methods: A total of 38 women were included in this study, with the main complaint being the inability to conceive or maintain pregnancy. Medical examination, laboratory tests, ultrasound of the pelvic organs and hysteroscopy were performed. After that, whole blood was taken to prepare an autologous PRP; then, the PRP was inserted into the uterine using an intrauterine catheter in the first phase of the menstrual cycle (1–7 procedures). The primary outcome of this study was an increase in endometrial thickness and improvement of the receptive endometrial layer. The secondary outcome was pregnancy rate. This was a single-center prospective interventional clinical study. Results: Statistical analysis of changes in endometrial thickness after PRP therapy showed that endometrial thickness indicators after treatment significantly exceeded the values before the intervention. This may be evidence of the effectiveness of PRP therapy for thin endometrium. When analyzing pregnancy status, it was noted that after receiving PRP, more than half (56% of cases) became pregnant and the majority of them successfully gave birth. Conclusions: Based on the results of our study, we can conclude that intrauterine injection of PRP may be a new therapeutic approach in the treatment of thin endometrium and associated infertility. The use of PRP demonstrated effectiveness in increasing the thickness of the endometrium, regardless of pregnancy, while the secondary indicator was the frequency of successful pregnancies among the participants.

Introduction: CAR-T cell therapy is the newest and most effective treatment method for resistant forms of B-cell hematological malignancies; however, it has until now remained unavailable in Kazakhstan. The first and critically important step in the manufacturing of CAR-T products is apheresis-based leukapheresis — a procedure that determines the quality of the starting cellular material for genetic modification of T lymphocytes. In the Republic of Kazakhstan, this procedure was performed within the framework of a national scientific and technical program for the implementation of CAR-T therapy. Objective: To study the parameters of apheresis-based leukapheresis and to characterize the cellular composition of the obtained mononuclear cell concentrate in order to assess its suitability as starting material for the manufacturing of CAR-T products. Materials and Methods: At the Department of Cell Technologies of the Scientific and Production Center of Transfusiology (Astana), 12 leukapheresis procedures were performed in 7 healthy donors and 5 patients with oncohematological diseases. An automated separator Spectra Optia (Terumo BCT, USA) was used with the Mononuclear Cell Collection program. The volume of processed blood, procedure duration, product cellularity, CD3⁺ T-cell content, and sterility were assessed. Results: All 12 procedures were completed without complications. The mean volume of processed blood was 9549.5 mL (1.0–2.6 blood volumes), and the mean duration was 230.8 min. Cell yield varied: total leukocyte count ranged from 6.5×10⁹ to 32.1×10⁹ (mean 14.4±8.0×10⁹), and CD3⁺ T-lymphocyte content ranged from 129.1×10⁷ to 1629.7×10⁷ cells per dose. Products from all participants were sterile and deemed suitable for CAR-T cell manufacturing. Differences were noted between the donor and patient groups; however, due to the small sample size, statistical analysis was not performed. Conclusions: Apheresis-based leukapheresis yields a cellular concentrate that fully meets the requirements for initiating the manufacturing of CAR-T products. This work represents the first standardized protocol in Kazakhstan for obtaining clinically significant cellular material for CAR-T cell manufacturing and lays the foundation for the development of national quality criteria. Funding: Program-Targeted Funding of the Ministry of Health of the Republic of Kazakhstan BR25293293 "Implementation of chimeric antigen receptor (CAR)-T cell therapy technology for hematological tumors into practical healthcare."

Objective. To assess the level of blood donors` satisfaction with the services provided by the Research and Production Center of Transfusiology in Astana for the period from 2022 to 2024 and to formulate recommendations for improving the quality of these services. Materials and methods. The donors` questionnaire included four questions regarding the availability of donor information, the quality of staff work during the manipulations and procedures, the level of staff communication skills and the conditions of stay in the RPCT. To assess the conditions for providing medical services to donors, a scale with the following points was proposed: excellent – 5 points, good – 4 points, normal – 3 points, bad – 2 points, very bad – 1 point. The processing of the survey results was carried out using the functionality of pivot tables in the Microsoft Excel program and descriptive statistics. Results. The final data on the conducted research demonstrate that most of the donors are satisfied with the quality of services provided by the RPCT on the 4 surveyed items: accessability of donor information, the quality of staff work during the manipulations and procedures, the level of staff communication skills and the conditions of stay in the RPCT. However, isolated negative answers which were recorded, allows us to conclude that there are some aspects in the provision of services to donors that can be improved. Conclusions. For further improvement of the availability of donor information, it is recommended to expand information materials, make more active use of digital and social platforms, introduce visual and interactive content, and study the information needs of donors regularly. This will increase satisfaction and attract more regular participants to the donor movement.